Analysts See $-1.48 EPS for The Medicines Company (MDCO); Brewin Dolphin Holdings PLC (LON:BRW) Covered By 7 Bullish Analysts Last Week

February 20, 2018 - By Vivian Currie

Analysts expect The Medicines Company (NASDAQ:MDCO) to report $-1.48 EPS on February, 27.They anticipate $0.19 EPS change or 14.73% from last quarter’s $-1.29 EPS. After having $-0.42 EPS previously, The Medicines Company’s analysts see 252.38% EPS growth. The stock increased 2.54% or $0.82 during the last trading session, reaching $33.16. About 1.84M shares traded or 25.92% up from the average. The Medicines Company (NASDAQ:MDCO) has risen 16.70% since February 20, 2017 and is uptrending. It has by 0.00% the S&P500.

Among 11 analysts covering Brewin Dolphin Holdings PLC (LON:BRW), 7 have Buy rating, 0 Sell and 4 Hold. Therefore 64% are positive. Brewin Dolphin Holdings PLC had 112 analyst reports since July 29, 2015 according to SRatingsIntel. The rating was upgraded by Peel Hunt to “Add” on Wednesday, July 27. The company was maintained on Wednesday, December 2 by Numis Securities. Numis Securities maintained it with “Hold” rating and GBX 265 target in Wednesday, November 30 report. The rating was maintained by Peel Hunt with “Add” on Thursday, January 26. Liberum Capital upgraded Brewin Dolphin Holdings PLC (LON:BRW) on Tuesday, December 8 to “Buy” rating. The company was maintained on Friday, June 2 by Macquarie Research. Peel Hunt maintained the shares of BRW in report on Wednesday, May 17 with “Add” rating. Canaccord Genuity maintained Brewin Dolphin Holdings PLC (LON:BRW) on Wednesday, November 30 with “Hold” rating. Canaccord Genuity maintained it with “Hold” rating and GBX 335 target in Wednesday, July 26 report. The firm has “Neutral” rating given on Thursday, September 24 by Macquarie Research. See Brewin Dolphin Holdings PLC (LON:BRW) latest ratings:

29/01/2018 Broker: Barclays Capital Rating: Overweight Old Target: GBX 410.00 New Target: GBX 430.00 Maintain
25/01/2018 Broker: Canaccord Genuity Rating: Hold Old Target: GBX 365.00 New Target: GBX 365.00 Maintain
25/01/2018 Broker: Numis Securities Rating: Hold Old Target: GBX 340.00 New Target: GBX 340.00 Maintain
25/01/2018 Broker: Peel Hunt Rating: Buy Old Target: GBX 390.00 New Target: GBX 390.00 Maintain
25/01/2018 Broker: Shore Capital Rating: Buy Maintain
25/01/2018 Broker: Liberum Capital Rating: Buy Old Target: GBX 416.00 New Target: GBX 416.00 Maintain
12/01/2018 Broker: Liberum Capital Rating: Buy Old Target: GBX 416.00 New Target: GBX 416.00 Maintain
22/12/2017 Broker: Canaccord Genuity Rating: Hold Old Target: GBX 335.00 New Target: GBX 365.00 Reiteration
29/11/2017 Broker: Canaccord Genuity Rating: Hold New Target: GBX 335.00 Maintain
30/11/2017 Broker: Barclays Capital Rating: Overweight New Target: GBX 410.00 Maintain

Since December 7, 2017, it had 1 insider purchase, and 1 insider sale for $1.60 million activity. ESHELMAN FREDRIC N had bought 200,000 shares worth $5.31 million. $3.71M worth of stock was sold by MEANWELL CLIVE on Friday, December 15.

The Medicines Company, a biopharmaceutical company, provides medicines for patients in acute and intensive care hospitals worldwide. The company has market cap of $2.39 billion. The firm markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for patients undergoing percutaneous coronary intervention; Ionsys, a fentanyl iontophoretic transdermal system for the short term management of acute postoperative pain for adults requiring opioid analgesia in the hospital. It currently has negative earnings. It also markets Minocin IV, an intravenous formulation of a tetracycline-class antibiotic used for the treatment of infections due to susceptible strains of designated gram-negative bacteria; and Orbactiv, an intravenous antibiotic used for the treatment of adult patients with acute bacterial skin and skin structure infections, or caused or suspected to be caused by susceptible isolates of designated gram-positive microorganisms.

Investors sentiment decreased to 0.78 in 2017 Q3. Its down 0.44, from 1.22 in 2017Q2. It worsened, as 32 investors sold The Medicines Company shares while 64 reduced holdings. 19 funds opened positions while 56 raised stakes. 85.15 million shares or 1.36% less from 86.33 million shares in 2017Q2 were reported. Zurcher Kantonalbank (Zurich Cantonalbank) stated it has 0% in The Medicines Company (NASDAQ:MDCO). Teachers Retirement Systems Of The State Of Kentucky has invested 0.07% of its portfolio in The Medicines Company (NASDAQ:MDCO). Stoneridge Inv Ptnrs Lc accumulated 25,351 shares. Atika Mgmt reported 0.83% of its portfolio in The Medicines Company (NASDAQ:MDCO). Sarissa Capital Mgmt Limited Partnership reported 20.03% in The Medicines Company (NASDAQ:MDCO). Fmr Ltd Liability Company stated it has 10.90 million shares or 0.05% of all its holdings. Guggenheim Lc has 123,742 shares. Parkside Bancshares And Tru holds 0% or 40 shares in its portfolio. Prudential Financial holds 0.01% or 108,442 shares in its portfolio. Bank & Trust Of Montreal Can invested in 3,186 shares. Moreover, Eagle Asset Mngmt Incorporated has 0.18% invested in The Medicines Company (NASDAQ:MDCO) for 814,434 shares. Envestnet Asset Mgmt invested in 2,114 shares. Arizona State Retirement Systems accumulated 33,196 shares. Manufacturers Life Insur Co The stated it has 0% in The Medicines Company (NASDAQ:MDCO). 2.81M were accumulated by Bridger Mgmt Lc.

Among 11 analysts covering The Medicines Co (NASDAQ:MDCO), 11 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. The Medicines Co had 35 analyst reports since August 28, 2015 according to SRatingsIntel. The rating was maintained by Jefferies with “Buy” on Monday, June 26. The rating was maintained by H.C. Wainwright on Tuesday, July 25 with “Buy”. Oppenheimer maintained the shares of MDCO in report on Monday, August 31 with “Market Perform” rating. As per Monday, November 16, the company rating was maintained by RBC Capital Markets. As per Wednesday, November 4, the company rating was initiated by Chardan Capital Markets. On Thursday, August 10 the stock rating was maintained by Oppenheimer with “Hold”. Jefferies maintained The Medicines Company (NASDAQ:MDCO) on Wednesday, August 2 with “Buy” rating. The firm has “Buy” rating given on Wednesday, August 9 by Cowen & Co. On Monday, August 31 the stock rating was maintained by RBC Capital Markets with “Outperform”. The firm earned “Outperform” rating on Wednesday, November 16 by RBC Capital Markets.

Brewin Dolphin Holdings PLC, together with its subsidiaries, provides wealth management services in the United Kingdom, the Channel Islands, and the Republic of Ireland. The company has market cap of 953.67 million GBP. It also offers investment management, financial planning, advisory, managed portfolio, and Brewin portfolio services, as well as custody, trade execution, and settlement services to private clients, charities, corporates, and intermediaries. It has a 21.8 P/E ratio.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: